Performance evaluation of FlowCytomix assays to quantify cytokines in patients with rheumatoid arthritis
- PMID: 26629129
- PMCID: PMC4659018
Performance evaluation of FlowCytomix assays to quantify cytokines in patients with rheumatoid arthritis
Abstract
Objectives: To compare the cytokine profile in RA patients and healthy control by using two methods-FlowCytomix assay and traditional ELISA.
Methods: Cytokine levels were evaluated by FlowCytomix assay and ELISA in serum and supernatants of peripheral blood mononuclear cells (PBMC) cultures with and without stimulation by phytohaemagglutinin (PHA).
Results: The levels of IL-6, IL-1β, and TNF-α were significantly higher in sera of RA patients than those of healthy controls. The levels of IL-22, IL-6, IL-1β, TNF-α, and IL-10 were higher in unstimulated PBMC culture supernatant of RA patients than those of healthy controls. PHA stimulation significantly increased the production of proinflammatory cytokines from PBMC with RA patients. Compared with detectable cytokine levels in sera, cytokine concentration in the supernatant of PBMCs was remarkably higher. FlowCytomix and ELISA showed significant correlation in detecting cytokines. However, the FlowCytomix assay detected more cytokines than ELISA.
Conclusion: The supernatant of PBMCs provide a fine condition for the study of cytokine production because of the lack of interference factors in sera. The FlowCytomix assay is more sensitive than ELISA in detecting cytokines from RA patients. Multiple cytokine signatures using FlowCytomix assay may represent a more realistic approach in the future of personalized medicine in RA.
Keywords: Cytokine profile; ELISA; FlowCytomix assay; rheumatoid arthritis.
Figures
Similar articles
-
Th1/Th17 Cytokine Profile is Induced by Macrophage Migration Inhibitory Factor in Peripheral Blood Mononuclear Cells from Rheumatoid Arthritis Patients.Curr Mol Med. 2018;18(10):679-688. doi: 10.2174/1566524019666190129123240. Curr Mol Med. 2018. PMID: 30698113 Clinical Trial.
-
Heterogeneity of the cytokinome in undifferentiated arthritis progressing to rheumatoid arthritis and its change in the course of therapy. Move toward personalized medicine.Cytokine. 2017 Sep;97:1-13. doi: 10.1016/j.cyto.2017.05.012. Epub 2017 May 25. Cytokine. 2017. PMID: 28551592
-
Expression of interleukin-18 and its monokine-directed function in rheumatoid arthritis.Rheumatology (Oxford). 2001 Mar;40(3):302-9. doi: 10.1093/rheumatology/40.3.302. Rheumatology (Oxford). 2001. PMID: 11285378
-
Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion.Arthritis Res. 2000;2(1):65-74. doi: 10.1186/ar70. Arthritis Res. 2000. PMID: 11219391 Free PMC article.
-
[Cytokines in children with immunodeficiencies].Folia Med Cracov. 1999;40(1-2):5-97. Folia Med Cracov. 1999. PMID: 10909468 Review. Polish.
Cited by
-
Saliva and Serum Cytokine Profiles During Oral Ulceration in Behçet's Disease.Front Immunol. 2021 Dec 22;12:724900. doi: 10.3389/fimmu.2021.724900. eCollection 2021. Front Immunol. 2021. PMID: 35003055 Free PMC article.
-
Changes in inflammatory protein and lipid mediator profiles persist after antitubercular treatment of pulmonary and extrapulmonary tuberculosis: A prospective cohort study.Cytokine. 2019 Nov;123:154759. doi: 10.1016/j.cyto.2019.154759. Epub 2019 Jun 18. Cytokine. 2019. PMID: 31226436 Free PMC article. Clinical Trial.
-
Analysis of PD-1 and Tim-3 expression on CD4+ T cells of patients with rheumatoid arthritis; negative association with DAS28.Clin Rheumatol. 2018 Aug;37(8):2063-2071. doi: 10.1007/s10067-018-4076-4. Epub 2018 Apr 7. Clin Rheumatol. 2018. PMID: 29626269
References
-
- Mcinnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7:429–442. - PubMed
-
- Das S, Vital EM, Horton S, Bryer D, EI-Sherbiny Y, Rawstron AC, Ponchel F, Emery P, Buch MH. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Ann Rheum Dis. 2014;73:909–912. - PubMed
-
- Zivojinovic SM, Pejnovic NN, Sefik-Bukilica MN, Kovacevic LV, Soldatovic II, Damjanov NS. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis. J Rheumatol. 2012;39:18–21. - PubMed
LinkOut - more resources
Full Text Sources